{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,10,28]],"date-time":"2025-10-28T05:53:08Z","timestamp":1761630788706},"reference-count":36,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2017,6,6]],"date-time":"2017-06-06T00:00:00Z","timestamp":1496707200000},"content-version":"unspecified","delay-in-days":0,"URL":"http:\/\/www.springer.com\/tdm"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Z Rheumatol"],"published-print":{"date-parts":[[2018,2]]},"DOI":"10.1007\/s00393-017-0330-4","type":"journal-article","created":{"date-parts":[[2017,6,6]],"date-time":"2017-06-06T08:37:52Z","timestamp":1496738272000},"page":"28-39","update-policy":"http:\/\/dx.doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":5,"title":["Sicherheit und Wirksamkeitshinweise zum Off-label-Einsatz von Biologikatherapien nach Versagen\n\t\t\tkonventioneller Therapien bei Patienten mit entz\u00fcndlich rheumatischen Erkrankungen"],"prefix":"10.1007","volume":"77","author":[{"given":"F.","family":"Proft","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"H.","family":"Schulze-Koops","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"M.","family":"Grunke","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"E.","family":"Schrezenmeier","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"F.","family":"Halleck","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"J.","family":"Henes","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"L.","family":"Unger","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"E.","family":"Schmidt","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"C.","family":"Fiehn","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"A.","family":"Jacobi","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"C.","family":"Iking-Konert","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"C.","family":"Kneitz","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"R. E.","family":"Schmidt","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"B.","family":"Bannert","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"R. E.","family":"Voll","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"R.","family":"Fischer-Betz","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"I.","family":"K\u00f6tter","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"H. P.","family":"Tony","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"J.","family":"Holle","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"M.","family":"Aringer","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"A.","family":"Erler","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"F.","family":"Behrens","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"G. R.","family":"Burmester","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"T.","family":"D\u00f6rner","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2017,6,6]]},"reference":[{"key":"330_CR1","doi-asserted-by":"crossref","first-page":"17","DOI":"10.1136\/annrheumdis-2016-209775","volume":"76","author":"R Agca","year":"2017","unstructured":"Agca R, Heslinga SC, Rollefstad S, Heslinga M, McInnes IB, Peters MJ, Kvien TK, Dougados M, Radner H, Atzeni F, Primdahl J, Sodergren A, Wallberg Jonsson S, van Rompay J, Zabalan C, Pedersen TR, Jacobsson L, de Vlam K, Gonzalez-Gay MA, Semb AG, Kitas GD, Smulders YM, Szekanecz Z, Sattar N, Symmons DP, Nurmohamed MT (2017) EULAR recommendations for cardiovascular disease risk management in patients with rheumatoid arthritis and other forms of inflammatory joint disorders: 2015\/2016 update. Ann Rheum Dis 76:17\u201328","journal-title":"Ann Rheum Dis"},{"key":"330_CR2","doi-asserted-by":"crossref","first-page":"1690","DOI":"10.1002\/art.24092","volume":"59","author":"JA Avina-Zubieta","year":"2008","unstructured":"Avina-Zubieta JA, Choi HK, Sadatsafavi M, Etminan M, Esdaile JM, Lacaille D (2008) Risk of cardiovascular mortality in patients with rheumatoid arthritis: a\u00a0meta-analysis of observational studies. Arthritis Rheum 59:1690\u20131697","journal-title":"Arthritis Rheum"},{"key":"330_CR3","doi-asserted-by":"crossref","first-page":"302","DOI":"10.1111\/bjd.13633","volume":"173","author":"YT Cho","year":"2015","unstructured":"Cho YT, Chu CY, Wang LF (2015) First-line combination therapy with rituximab and corticosteroids provides a\u00a0high complete remission rate in moderate-to-severe bullous pemphigoid. Br J Dermatol 173:302\u2013304","journal-title":"Br J Dermatol"},{"key":"330_CR4","doi-asserted-by":"crossref","first-page":"1385","DOI":"10.1007\/s00228-014-1746-2","volume":"70","author":"I Danes","year":"2014","unstructured":"Danes I, Agusti A, Vallano A, Alerany C, Martinez J, Bosch JA, Ferrer A, Gratacos L, Perez A, Olmo M, Marron SM, Valderrama A, Bonafont X (2014) Outcomes of off-label drug uses in hospitals: a\u00a0multicentric prospective study. Eur J Clin Pharmacol 70:1385\u20131393","journal-title":"Eur J Clin Pharmacol"},{"key":"330_CR5","doi-asserted-by":"crossref","first-page":"82","DOI":"10.1016\/j.autrev.2009.08.007","volume":"9","author":"T Dorner","year":"2009","unstructured":"Dorner T, Isenberg D, Jayne D, Wiendl H, Zillikens D, Burmester G, International Roundtable on BcaTTfI (2009) Current status on B\u2011cell depletion therapy in autoimmune diseases other than rheumatoid arthritis. Autoimmun Rev 9:82\u201389","journal-title":"Autoimmun Rev"},{"key":"330_CR6","doi-asserted-by":"crossref","first-page":"159","DOI":"10.1159\/000430849","volume":"130","author":"FC Fervenza","year":"2015","unstructured":"Fervenza FC, Canetta PA, Barbour SJ, Lafayette RA, Rovin BH, Aslam N, Hladunewich MA, Irazabal MV, Sethi S, Gipson DS, Reich HN, Brenchley P, Kretzler M, Radhakrishnan J, Hebert LA, Gipson PE, Thomas LF, McCarthy ET, Appel GB, Jefferson JA, Eirin A, Lieske JC, Hogan MC, Greene EL, Dillon JJ, Leung N, Sedor JR, Rizk DV, Blumenthal SS, Lasic LB, Juncos LA, Green DF, Simon J, Sussman AN, Philibert D, Cattran DC, Mentor Consortium group (2015) A multicenter randomized controlled trial of rituximab versus cyclosporine in the treatment of idiopathic membranous nephropathy (MENTOR). Nephron 130:159\u2013168","journal-title":"Nephron"},{"key":"330_CR7","doi-asserted-by":"publisher","unstructured":"Fiehn C, Unger L, Schulze-Koops H et\u00a0al. (2017) Rituximab zur Behandlung von Poly- und Dermatomyositis. Die Ergebnisse des GRAID-2-Registers. Z Rheumatol. doi:\n                        10.1007\/s00393-017-0327-z","DOI":"10.1007\/s00393-017-0327-z"},{"key":"330_CR8","doi-asserted-by":"crossref","first-page":"409","DOI":"10.7326\/M14-2470","volume":"163","author":"NN Haroon","year":"2015","unstructured":"Haroon NN, Paterson JM, Li P, Inman RD, Haroon N (2015) Patients with ankylosing spondylitis have increased cardiovascular and cerebrovascular mortality: a population-based study. Ann Intern Med 163:409\u2013416","journal-title":"Ann Intern Med"},{"key":"330_CR9","doi-asserted-by":"publisher","unstructured":"Henes JC, Proft F, Schulze-Koops et\u00a0al. (2017) Off-label-Biologikatherapie bei Patienten mit Gro\u00dfgef\u00e4\u00dfvaskulitiden und\/oder Polymyalgia rheumatica. Wirksamkeits- und Sicherheitsanalyse eines nationalen Registers (GRAID2). Z Rheumatol. doi:\n                        10.1007\/s00393-017-0325-1","DOI":"10.1007\/s00393-017-0325-1"},{"key":"330_CR10","doi-asserted-by":"publisher","unstructured":"Joly P, Maho-Vaillant M, Prost-Squarcioni C, Hebert V, Houivet E, Calbo S, Caillot F, Golinski ML, Labeille B, Picard-Dahan C, Paul C, Richard MA, Bouaziz JD, Duvert-Lehembre S, Bernard P, Caux F, Alexandre M, Ingen-Housz-Oro S, Vabres P, Delaporte E, Quereux G, Dupuy A, Debarbieux S, Avenel-Audran M, D\u2019Incan M, Bedane C, B\u00e9n\u00e9ton N, Jullien D, Dupin N, Misery L, Machet L, Beylot-Barry M, Dereure O, Sassolas B, Vermeulin T, Benichou J, Musette P; French study group on autoimmune bullous skin diseases (2017) First-line rituximab combined with short-term prednisone versus prednisone alone for the treatment of pemphigus (Ritux 3): a prospective, multicentre, parallel-group, open-label randomised trial. Lancet 389(10083):2031\u20132040. doi:\n                        10.1016\/S0140-6736(17)30070-3\n                        \n                    . Epub 2017 Mar 22.","DOI":"10.1016\/S0140-6736(17)30070-3"},{"key":"330_CR11","doi-asserted-by":"crossref","first-page":"211","DOI":"10.1056\/NEJMoa0909169","volume":"363","author":"RB Jones","year":"2010","unstructured":"Jones RB, Tervaert JW, Hauser T, Luqmani R, Morgan MD, Peh CA, Savage CO, Segelmark M, Tesar V, van Paassen P, Walsh D, Walsh M, Westman K, Jayne DR, European Vasculitis Study Group (2010) Rituximab versus cyclophosphamide in ANCA-associated renal vasculitis. N\u00a0Engl J Med 363:211\u2013220","journal-title":"N Engl J Med"},{"key":"330_CR12","doi-asserted-by":"crossref","first-page":"1188","DOI":"10.1136\/annrheumdis-2013-204522","volume":"74","author":"S Jordan","year":"2015","unstructured":"Jordan S, Distler JH, Maurer B, Huscher D, van Laar JM, Allanore Y, Distler O, EUSTAR Rituximab study group (2015) Effects and safety of rituximab in systemic sclerosis: an analysis from the European Scleroderma Trial and Research (EUSTAR) group. Ann Rheum Dis 74:1188\u20131194","journal-title":"Ann Rheum Dis"},{"key":"330_CR13","doi-asserted-by":"crossref","first-page":"552","DOI":"10.1016\/j.jaad.2010.07.032","volume":"65","author":"M Kasperkiewicz","year":"2011","unstructured":"Kasperkiewicz M, Shimanovich I, Ludwig RJ, Rose C, Zillikens D, Schmidt E (2011) Rituximab for treatment-refractory pemphigus and pemphigoid: a\u00a0case series of 17 patients. J\u00a0Am Acad Dermatol 65:552\u2013558","journal-title":"J Am Acad Dermatol"},{"key":"330_CR14","first-page":"727","volume":"10","author":"M Kasperkiewicz","year":"2012","unstructured":"Kasperkiewicz M, Eming R, Behzad M, Hunzelmann N, Meurer M, Schulze-Koops H, Von Wussow P, Hertl M, Zillikens D, Freivogel K, D\u00f6rner T, Schmidt E (2012) Efficacy and safety of rituximab in pemphigus: experience of the German Registry of Autoimmune Diseases. J\u00a0Dtsch Dermatol Ges 10:727\u2013732","journal-title":"J Dtsch Dermatol Ges"},{"key":"330_CR15","doi-asserted-by":"crossref","first-page":"2630","DOI":"10.1016\/S0140-6736(16)00232-4","volume":"387","author":"D Khanna","year":"2016","unstructured":"Khanna D, Denton CP, Jahreis A, van Laar JM, Frech TM, Anderson ME, Baron M, Chung L, Fierlbeck G, Lakshminarayanan S, Allanore Y, Pope JE, Riemekasten G, Steen V, Muller-Ladner U, Lafyatis R, Stifano G, Spotswood H, Chen-Harris H, Dziadek S, Morimoto A, Sornasse T, Siegel J, Furst DE (2016) Safety and efficacy of subcutaneous tocilizumab in adults with systemic sclerosis (faSScinate): a\u00a0phase 2, randomised, controlled trial. Lancet 387:2630\u20132640","journal-title":"Lancet"},{"key":"330_CR16","doi-asserted-by":"crossref","first-page":"835","DOI":"10.1016\/j.jaad.2016.01.020","volume":"74","author":"A Maley","year":"2016","unstructured":"Maley A, Warren M, Haberman I, Swerlick R, Kharod-Dholakia B, Feldman R (2016) Rituximab combined with conventional therapy versus conventional therapy alone for the treatment of mucous membrane pemphigoid (MMP). J\u00a0Am Acad Dermatol 74:835\u2013840","journal-title":"J Am Acad Dermatol"},{"key":"330_CR17","doi-asserted-by":"crossref","first-page":"960","DOI":"10.1002\/art.27314","volume":"62","author":"JM Meijer","year":"2010","unstructured":"Meijer JM, Meiners PM, Vissink A, Spijkervet FK, Abdulahad W, Kamminga N, Brouwer E, Kallenberg CG, Bootsma H (2010) Effectiveness of rituximab treatment in primary Sjogren\u2019s syndrome: a\u00a0randomized, double-blind, placebo-controlled trial. Arthritis Rheum 62:960\u2013968","journal-title":"Arthritis Rheum"},{"key":"330_CR18","doi-asserted-by":"crossref","first-page":"222","DOI":"10.1002\/art.27233","volume":"62","author":"JT Merrill","year":"2010","unstructured":"Merrill JT, Neuwelt CM, Wallace DJ, Shanahan JC, Latinis KM, Oates JC, Utset TO, Gordon C, Isenberg DA, Hsieh HJ, Zhang D, Brunetta PG (2010) Efficacy and safety of rituximab in moderately-to-severely active systemic lupus erythematosus: the randomized, double-blind, phase II\/III systemic lupus erythematosus evaluation of rituximab trial. Arthritis Rheum 62:222\u2013233","journal-title":"Arthritis Rheum"},{"key":"330_CR19","first-page":"1864","volume":"34","author":"CC Mok","year":"2007","unstructured":"Mok CC, Ho LY, To CH (2007) Rituximab for refractory polymyositis: an open-label prospective study. J\u00a0Rheumatol 34:1864\u20131868","journal-title":"J Rheumatol"},{"key":"330_CR20","doi-asserted-by":"crossref","first-page":"35","DOI":"10.2174\/1574886310666151014115127","volume":"11","author":"E Molinelli","year":"2016","unstructured":"Molinelli E, Campanati A, Ganzetti G, Offidani A (2016) Biologic therapy in immune mediated inflammatory disease: basic science and clinical concepts. Curr Drug Saf 11:35\u201343","journal-title":"Curr Drug Saf"},{"key":"330_CR21","doi-asserted-by":"crossref","first-page":"314","DOI":"10.1002\/art.37754","volume":"65","author":"CV Oddis","year":"2013","unstructured":"Oddis CV, Reed AM, Aggarwal R, Rider LG, Ascherman DP, Levesque MC, Barohn RJ, Feldman BM, Harris-Love MO, Koontz DC, Fertig N, Kelley SS, Pryber SL, Miller FW, Rockette HE, Group RIMS (2013) Rituximab in the treatment of refractory adult and juvenile dermatomyositis and adult polymyositis: a\u00a0randomized, placebo-phase trial. Arthritis Rheum 65:314\u2013324","journal-title":"Arthritis Rheum"},{"key":"330_CR22","doi-asserted-by":"publisher","unstructured":"Proft F, Henes JC, Fleck M et\u00a0al. (2017) Wirksamkeits- und Sicherheitsanalyse von Off-label-Biologikatherapien bei Patienten mit autoinflammatorischen Erkrankungen. Erfahrungen aus einem Deutschen Register (GRAID2). Z Rheumatol. doi:\n                        10.1007\/s00393-017-0329-x","DOI":"10.1007\/s00393-017-0329-x"},{"key":"330_CR23","first-page":"468","volume":"28","author":"M Ramos-Casals","year":"2010","unstructured":"Ramos-Casals M, Garcia-Hernandez FJ, de Ramon E, Callejas JL, Martinez-Berriotxoa A, Pallares L, Caminal-Montero L, Selva-O\u2019Callaghan A, Oristrell J, Hidalgo C, Perez-Alvarez R, Mico ML, Medrano F, de la Gomez Torre R, Diaz-Lagares C, Camps M, Ortego N, Sanchez-Roman J, BIOGEAS Study Group (2010) Off-label use of rituximab in 196 patients with severe, refractory systemic autoimmune diseases. Clin Exp Rheumatol 28:468\u2013476","journal-title":"Clin Exp Rheumatol"},{"key":"330_CR24","doi-asserted-by":"crossref","first-page":"2153","DOI":"10.3899\/jrheum.120482","volume":"39","author":"P Roll","year":"2012","unstructured":"Roll P, Ostermeier E, Haubitz M, Lovric S, Unger L, Holle J, Kotter I, Henes JC, Bergner R, Rubbert-Roth A, Specker C, Schulze-Koops H, Muller-Ladner U, Fleck M, Burmester GR, Hiepe F, Heitmann S, Aringer M, Fischer-Betz R, Dorner T, Tony HP (2012) Efficacy and safety of rituximab treatment in patients with antineutrophil cytoplasmic antibody-associated vasculitides: results from a\u00a0German registry (GRAID). J\u00a0Rheumatol 39:2153\u20132156","journal-title":"J Rheumatol"},{"key":"330_CR25","doi-asserted-by":"crossref","first-page":"417","DOI":"10.1056\/NEJMoa1213277","volume":"369","author":"U Specks","year":"2013","unstructured":"Specks U, Merkel PA, Seo P, Spiera R, Langford CA, Hoffman GS, Kallenberg CG, St Clair EW, Fessler BJ, Ding L, Viviano L, Tchao NK, Phippard DJ, Asare AL, Lim N, Ikle D, Jepson B, Brunetta P, Allen NB, Fervenza FC, Geetha D, Keogh K, Kissin EY, Monach PA, Peikert T, Stegeman C, Ytterberg SR, Mueller M, Sejismundo LP, Mieras K, Stone JH, RAVE-ITN Research Group (2013) Efficacy of remission-induction regimens for ANCA-associated vasculitis. N\u00a0Engl J Med 369:417\u2013427","journal-title":"N Engl J Med"},{"key":"330_CR26","doi-asserted-by":"crossref","first-page":"221","DOI":"10.1056\/NEJMoa0909905","volume":"363","author":"JH Stone","year":"2010","unstructured":"Stone JH, Merkel PA, Spiera R, Seo P, Langford CA, Hoffman GS, Kallenberg CG, St Clair EW, Turkiewicz A, Tchao NK, Webber L, Ding L, Sejismundo LP, Mieras K, Weitzenkamp D, Ikle D, Seyfert-Margolis V, Mueller M, Brunetta P, Allen NB, Fervenza FC, Geetha D, Keogh KA, Kissin EY, Monach PA, Peikert T, Stegeman C, Ytterberg SR, Specks U, Group R (2010) Rituximab versus cyclophosphamide for ANCA-associated vasculitis. N\u00a0Engl J Med 363:221\u2013232","journal-title":"N Engl J Med"},{"issue":"Suppl","key":"330_CR27","first-page":"1204","volume":"68","author":"JH Stone","year":"2016","unstructured":"Stone JH, Tuckwell K, Dimonaco S, Klearman M, Aringer M, Blockmans D, Brouwer E, Cid MC, Dasgupta B, Rech J, Salvarani C, Spiera R, Unizony SH, Collinson N (2016) Efficacy and safety of tocilizumab in patients with giant cell arteritis: primary andsecondary outcomes from a\u00a0phase 3, randomized, double-blind, placebo-controlled trial [abstract]. Arthritis Rheumatol 68(Suppl):1204\u20131205","journal-title":"Arthritis Rheumatol"},{"key":"330_CR28","unstructured":"Svensson J, Holmqvist M, Tjarnlund A, Dastmalchi M, Hanna B, Magnusson Bucher S, Lundberg IE (2016) Use of biologic agents in idiopathic inflammatory myopathies in Sweden: a\u00a0descriptive study of real life treatment. Clin Exp Rheumatol  2016 Dec 9. [Epub ahead of print]"},{"key":"330_CR29","doi-asserted-by":"crossref","first-page":"191","DOI":"10.3109\/s10165-007-0565-z","volume":"17","author":"Y Tanaka","year":"2007","unstructured":"Tanaka Y, Yamamoto K, Takeuchi T, Nishimoto N, Miyasaka N, Sumida T, Shima Y, Takada K, Matsumoto I, Saito K, Koike T (2007) A multicenter phase I\/II trial of rituximab for refractory systemic lupus erythematosus. Mod Rheumatol 17:191\u2013197","journal-title":"Mod Rheumatol"},{"key":"330_CR30","doi-asserted-by":"crossref","first-page":"2458","DOI":"10.1002\/art.27541","volume":"62","author":"B Terrier","year":"2010","unstructured":"Terrier B, Amoura Z, Ravaud P, Hachulla E, Jouenne R, Combe B, Bonnet C, Cacoub P, Cantagrel A, de Bandt M, Fain O, Fautrel B, Gaudin P, Godeau B, Harle JR, Hot A, Kahn JE, Lambotte O, Larroche C, Leone J, Meyer O, Pallot-Prades B, Pertuiset E, Quartier P, Schaerverbeke T, Sibilia J, Somogyi A, Soubrier M, Vignon E, Bader-Meunier B, Mariette X, Gottenberg JE, Club Rhumatismes et Inflammation (2010) Safety and efficacy of rituximab in systemic lupus erythematosus: results from 136 patients from the French AutoImmunity and Rituximab registry. Arthritis Rheum 62:2458\u20132466","journal-title":"Arthritis Rheum"},{"key":"330_CR31","doi-asserted-by":"crossref","first-page":"R75","DOI":"10.1186\/ar3337","volume":"13","author":"HP Tony","year":"2011","unstructured":"Tony HP, Burmester G, Schulze-Koops H, Grunke M, Henes J, Kotter I, Haas J, Unger L, Lovric S, Haubitz M, Fischer-Betz R, Chehab G, Rubbert-Roth A, Specker C, Weinerth J, Holle J, Muller-Ladner U, Konig R, Fiehn C, Burgwinkel P, Budde K, Sorensen H, Meurer M, Aringer M, Kieseier B, Erfurt-Berge C, Sticherling M, Veelken R, Ziemann U, Strutz F, von Wussow P, Meier FM, Hunzelmann N, Schmidt E, Bergner R, Schwarting A, Eming R, Hertl M, Stadler R, Schwarz-Eywill M, Wassenberg S, Fleck M, Metzler C, Zettl U, Westphal J, Heitmann S, Herzog AL, Wiendl H, Jakob W, Schmidt E, Freivogel K, Dorner T, GRAID investigators (2011) Safety and clinical outcomes of rituximab therapy in patients with different autoimmune diseases: experience from a\u00a0national registry (GRAID). Arthritis Res Ther 13:R75","journal-title":"Arthritis Res Ther"},{"key":"330_CR32","doi-asserted-by":"publisher","unstructured":"Venhoff N, Thiel J, Proft F (2017) Off-label-Biologikatherapie von ANCA-assoziierten und nicht-ANCA-assoziierten Kleingef\u00e4\u00dfvaskulitiden. Wirksamkeits- und Sicherheitsanalyse eines nationalen Registers (GRAID2). Z Rheumatol. doi:\n                        10.1007\/s00393-017-0315-3","DOI":"10.1007\/s00393-017-0315-3"},{"key":"330_CR33","doi-asserted-by":"crossref","first-page":"107","DOI":"10.1186\/s12891-015-0562-x","volume":"16","author":"M Vilsteren van","year":"2015","unstructured":"van Vilsteren M, Boot CR, Knol DL, van Schaardenburg D, Voskuyl AE, Steenbeek R, Anema JR (2015) Productivity at work and quality of life in patients with rheumatoid arthritis. BMC Musculoskelet Disord 16:107","journal-title":"BMC Musculoskelet Disord"},{"key":"330_CR34","doi-asserted-by":"crossref","first-page":"1921","DOI":"10.1016\/S0140-6736(16)00560-2","volume":"387","author":"PM Villiger","year":"2016","unstructured":"Villiger PM, Adler S, Kuchen S, Wermelinger F, Dan D, Fiege V, Butikofer L, Seitz M, Reichenbach S (2016) Tocilizumab for induction and maintenance of remission in giant cell arteritis: a\u00a0phase 2, randomised, double-blind, placebo-controlled trial. Lancet 387:1921\u20131927","journal-title":"Lancet"},{"key":"330_CR35","doi-asserted-by":"crossref","first-page":"534","DOI":"10.1136\/annrheumdis-2016-209668","volume":"76","author":"DJ Wallace","year":"2017","unstructured":"Wallace DJ, Strand V, Merrill JT, Popa S, Spindler AJ, Eimon A, Petri M, Smolen JS, Wajdula J, Christensen J, Li C, Diehl A, Vincent MS, Beebe J, Healey P, Sridharan S (2017) Efficacy and safety of an interleukin 6 monoclonal antibody for the treatment of systemic lupus erythematosus: a\u00a0phase II dose-ranging randomised controlled trial. Ann Rheum Dis 76:534\u2013542","journal-title":"Ann Rheum Dis"},{"key":"330_CR36","doi-asserted-by":"crossref","first-page":"608","DOI":"10.1002\/acr.22173","volume":"66","author":"M Yurkovich","year":"2014","unstructured":"Yurkovich M, Vostretsova K, Chen W, Avina-Zubieta JA (2014) Overall and cause-specific mortality in patients with systemic lupus erythematosus: a\u00a0meta-analysis of observational studies. Arthritis Care Res (Hoboken) 66:608\u2013616","journal-title":"Arthritis Care Res (Hoboken)"}],"container-title":["Zeitschrift f\u00fcr Rheumatologie"],"original-title":[],"language":"de","link":[{"URL":"http:\/\/link.springer.com\/article\/10.1007\/s00393-017-0330-4\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s00393-017-0330-4.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s00393-017-0330-4.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2018,2,5]],"date-time":"2018-02-05T08:21:48Z","timestamp":1517818908000},"score":1,"resource":{"primary":{"URL":"http:\/\/link.springer.com\/10.1007\/s00393-017-0330-4"}},"subtitle":["Ergebnisse eines nationalen Registers (GRAID2)"],"short-title":[],"issued":{"date-parts":[[2017,6,6]]},"references-count":36,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2018,2]]}},"alternative-id":["330"],"URL":"https:\/\/doi.org\/10.1007\/s00393-017-0330-4","relation":{},"ISSN":["0340-1855","1435-1250"],"issn-type":[{"value":"0340-1855","type":"print"},{"value":"1435-1250","type":"electronic"}],"subject":[],"published":{"date-parts":[[2017,6,6]]}}}